ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Pharmacokinetic and tissue distribution advantages of intraperitoneal oxaliplatin over systemic delivery: a swine model comparison of PIPAC and HPIPAC.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPeritoneal metastases are a common manifestation with a dismal prognosis in advanced gastric cancer. Systemic chemotherapy has limited efficacy in this setting due to poor drug penetration into the peritoneum. Intraperitoneal (IP) chemotherapy techniques such as Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and its hyperthermic variant, Hyperthermic Pressurized Intraperitoneal Aerosol Chemotherapy (HPIPAC), have emerged as targeted delivery methods to enhance peritoneal drug exposure while reducing systemic toxicity. This study compares the pharmacokinetics, tissue distribution, and peritoneal penetration of oxaliplatin administered via intravenous (IV) injection versus intraperitoneal chemotherapy using aerosolized drug delivery techniques, including PIPAC and HPIPAC.
methodsIn a swine model (n = 19), oxaliplatin was administered via IV (n = 5), PIPAC (n = 7), or HPIPAC (n = 7). Plasma oxaliplatin levels were measured at 14 time points over 6 h using liquid chromatography–tandem mass spectrometry. Tissue concentrations and tissue-to-plasma ratios were determined for major organs. Drug penetration into the peritoneum was visualized via matrix-assisted laser desorption/ionization mass spectrometry imaging.
resultsIV delivery resulted in rapid systemic exposure but minimal peritoneal concentrations (66.5 ng/mg). PIPAC and HPIPAC significantly enhanced peritoneal tissue concentration (5310.0 ng/mg and 2313.8 ng/mg, respectively) with markedly lower systemic exposure. The depth of tissue penetration was greater with IP delivery, with HPIPAC reaching an average of 2.69 mm.
conclusionsCompared to systemic IV chemotherapy, intraperitoneal delivery using aerosolized oxaliplatin under pressurized capnopneumoperitoneum achieved superior peritoneal drug concentration, deeper tissue penetration, and reduced systemic exposure. These findings validate PIPAC and HPIPAC as feasible and potential modalities for treating peritoneal metastases in gastric cancer.
Indexed as
Identifiers
41801509What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.